Literature DB >> 18204787

Induction of c-Myc-dependent cell proliferation through toll-like receptor 3 in head and neck cancer.

Ralph Pries1, Lisa Hogrefe, Lei Xie, Henning Frenzel, Carsten Brocks, Claudia Ditz, Barbara Wollenberg.   

Abstract

Protein expression of human toll-like receptors (TLR) 1-10 was measured in cell lines and solid tumors of head and neck squamous cell carcinoma (HNSCC). All HNSCC cell lines and 80% of solid tumors were found to express TLR3 as a predominantly intracellular protein, while no other TLR proteins were expressed. TLR3 has previously been shown to contribute to the activation of nuclear factor-kappaB (NF-kappaB), a transcription factor which promotes several types of human cancers. Significantly, NF-kappaB expression was strongest in protein extracts from carcinoma tissue in which TLR3 was overexpressed. Inhibition of TLR3 expression in permanent HNSCC cell lines resulted in decreased expression of the oncoprotein c-Myc resulting in decreased cell proliferation. Correspondingly, overexpression of human TLR3 in mouse fibroblasts resulted in an upregulation of c-Myc and increased sensitivity for PolyI:C-induced cell proliferation. Our data suggest that TLR3 contributes to the malignant phenotype leading to invasive carcinoma in HNSCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18204787

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  18 in total

1.  The dual role of TLR3 in metastatic cell line.

Authors:  Tanja Matijevic; Jasminka Pavelic
Journal:  Clin Exp Metastasis       Date:  2011-07-07       Impact factor: 5.150

Review 2.  Targeting pattern recognition receptors in cancer immunotherapy.

Authors:  Nadège Goutagny; Yann Estornes; Uzma Hasan; Serge Lebecque; Christophe Caux
Journal:  Target Oncol       Date:  2012-03-08       Impact factor: 4.493

3.  The role of toll-like receptors (TLRs) in pan-cancer.

Authors:  Runzhi Huang; Zehui Sun; Shuyuan Xian; Dianwen Song; Zhengyan Chang; Penghui Yan; Jie Zhang; Huabin Yin; Zixuan Zheng; Peng Hu; Zhenyu Li; Dan Huang; Yihan Liu; Chenyang Jiang; Man Li; Siqi Li; Tong Meng; Daoke Yang; Zongqiang Huang
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

4.  Downregulation of c-Myc is involved in TLR3-mediated tumor death of neuroblastoma xenografts.

Authors:  Li-Ling Lin; Chao-Cheng Huang; Chia-Ling Wu; Min-Tsui Wu; Wen-Ming Hsu; Jiin-Haur Chuang
Journal:  Lab Invest       Date:  2016-05-16       Impact factor: 5.662

5.  Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas.

Authors:  Camilla Rydberg; Anne Månsson; Rolf Uddman; Kristian Riesbeck; Lars-Olaf Cardell
Journal:  Immunology       Date:  2008-12-26       Impact factor: 7.397

Review 6.  Roles of Toll-Like Receptor 3 in Human Tumors.

Authors:  Xin Zheng; Song Li; Hui Yang
Journal:  Front Immunol       Date:  2021-04-27       Impact factor: 7.561

7.  Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma.

Authors:  Lovisa Farnebo; Arash Shahangian; Yunqin Lee; June Ho Shin; Ferenc A Scheeren; John B Sunwoo
Journal:  Oncotarget       Date:  2015-04-30

8.  Toll-like receptor gene polymorphisms in patients with myeloproliferative neoplasms.

Authors:  Marília Gonçalves Quirino; Luciana Conci Macedo; Katia Borgia Barbosa Pagnano; Sarah Pagliarini-E-Silva; Ana Maria Sell; Jeane Eliete Laguila Visentainer
Journal:  Mol Biol Rep       Date:  2021-06-30       Impact factor: 2.316

9.  Radio-sensitization of head and neck cancer cells by a combination of poly(I:C) and cisplatin through downregulation of survivin and c-IAP2.

Authors:  Martina Mikulandra; Antonio Kobescak; Benjamin Verillaud; Pierre Busson; Tanja Matijevic Glavan
Journal:  Cell Oncol (Dordr)       Date:  2018-09-04       Impact factor: 7.051

Review 10.  Toll-like receptors and cancer, particularly oral squamous cell carcinoma.

Authors:  Alison Mary Rich; Haizal Mohd Hussaini; Venkata P B Parachuru; Gregory J Seymour
Journal:  Front Immunol       Date:  2014-09-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.